FDA and EMA filings for Opdivo + Yervoy with limited chemotherapy are accepted in first-line lung cancer.

-Bristol Myers Squibb announced that the FDA has accepted its supplemental Biologics License Application (sBLA) for Opdivo (nivolumab) plus Yervoy (ipilimumab), administered concomitantly with a limited course of chemotherapy, for the first-line treatment of patients with metastatic or recurrent non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations. The FDA granted this application Priority Review with a Prescription Drug User Fee Act (PDUFA) goal date of 6 August 2020, in addition to granting FastTrack designation Additionally, the European Medicines Agency (EMA) validated a type II variation application for Opdivo plus Yervoy, combined with limited chemotherapy, for the same indication. Validation of the application confirms the submission is complete and begins the EMA’s centralized review process. This follows an announcement on March 26, 2020 that Ono Pharmaceutical Co., in partnership with Bristol Myers Squibb, submitted a supplemental application for Opdivo plus Yervoy combined with limited chemotherapy for consideration of manufacturing and marketing approval in Japan. The applications were based on results from the Phase III CheckMate -9LA trial. In October 2019, the company announced the trial met its primary endpoint of superior overall survival (OS) at a pre-specified interim analysis.